NASDAQ:CALC CalciMedica Q1 2025 Earnings Results & Report $1.17 -0.05 (-4.10%) Closing price 04:00 PM EasternExtended Trading$1.16 -0.01 (-0.85%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CalciMedica beat analyst earnings expectations in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$1.80 versus the -$2.15 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 14, 2025TimeBefore Market Opens CalciMedica EPS ResultsActual EPS-$1.80Consensus EPS -$2.15Beat/MissBeat by +$0.35One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersCalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CalciMedica Q1 2025 Earnings FAQ Did CalciMedica beat earnings estimates for Q1 2025? CalciMedica (NASDAQ:CALC) reported earnings of -$1.80 per share for Q1 2025, beating the consensus estimate of -$2.15. The report was announced on Wednesday, May 14, 2025. CalciMedica Earnings HeadlinesFY2026 EPS Estimates for CalciMedica Raised by HC WainwrightNovember 14, 2026 | americanbankingnews.comCalciMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 11, 2026 | marketscreener.comMWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 18 at 1:00 AM | Porter & Company (Ad)CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesNovember 10, 2026 | globenewswire.comCalciMedica (CALC) Set to Release Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comCalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 3, 2026 | globenewswire.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation. The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development. Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.